Effects of aleglitazar on cardiovascular risk factors in patients with stage 3 chronic kidney disease and type 2 diabetes

Autor:	A. Michael Lincoff, Markolf Hanefeld, Matthias Herz, Sylvie Meyer Reigner, Nadejda Mudie, Giancarlo Viberti, Klas Malmberg, Luis M. Ruilope, Teresa Urbanowska
Rok vydání:	2013
Předmět:	medicine.medical_specialty Aleglitazar business.industry Cardiovascular risk factors Type 2 diabetes medicine.disease chemistry.chemical_compound chemistry Internal medicine medicine In patient Stage (cooking) Cardiology and Cardiovascular Medicine business Kidney disease
Zdroj:	Atherosclerosis. 231:e3
ISSN:	0021-9150
DOI:	10.1016/j.atherosclerosis.2013.07.015
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1c800b6f5a8153c38dab32eb000ccc6a https://doi.org/10.1016/j.atherosclerosis.2013.07.015 Zobrazit plný text záznamu Full Text from ScienceDirect